ADAGIO MEDICAL Investor Presentation | June 2024 1 DISCLAIMER This investor presentation is for informational purposes only to assist interested parties in making their.
Using data from the PROVE-HF study, investigators conducted a subanalysis of outcomes among patients receiving sacubitril/valsartan who did and did not have ischemic heart disease.